Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Breakthrough Blood Test Shows Promise for Early Alzheimer’s Detection

NextEdge Admin

31 Jan 2024

3 min 12 sec

A recent study suggests that a blood test screening for phosphorylated tau (p-tau) protein could accurately detect Alzheimer’s disease even before symptoms manifest. The research focused on the biomarker p-tau217, associated with the simultaneous buildup of damaging proteins, beta-amyloid, and tau, in Alzheimer’s patients’ brains. Current diagnostic methods involve brain scans or spinal taps, which can be costly and inaccessible.

The study, published in JAMA Neurology, revealed that the blood test achieved up to 96% accuracy in identifying elevated beta-amyloid levels and up to 97% accuracy in identifying tau. The test’s accuracy matched that of advanced methods like cerebrospinal fluid tests and brain scans, marking a significant step toward making blood-based biomarkers a mainstream diagnostic tool.

The ALZpath pTau217 assay, a commercially available tool used in the study, demonstrated high accuracy. This blood test could complement or potentially replace more expensive and invasive procedures, offering a more accessible method for assessing Alzheimer’s risk.

The study included 786 participants, with the blood test exhibiting similar accuracy to spinal taps and brain scans. The researchers highlighted its potential to reduce the need for further testing in about 80% of cases, streamlining the diagnostic process and reducing costs.

Despite its high accuracy in identifying Alzheimer’s-related characteristics, the blood test’s limitations include its specificity to Alzheimer’s disease. A negative result does not rule out other causes of cognitive impairment, such as vascular dementia or Lewy body dementia.

Experts see this blood test as a promising step toward democratizing access to Alzheimer’s diagnostics. If widely adopted, it could allow individuals to make informed decisions about brain health and enable more proactive management of dementia risks. Routine blood tests for Alzheimer’s, like cholesterol screenings, may become commonplace, providing an early and cost-effective means of identifying high-risk individuals and facilitating timely interventions. The study’s findings suggest that combining a simple screening test with effective treatments could significantly impact individuals and society, potentially revolutionizing Alzheimer’s prevention, and neurology.